The effects of hydrocodone rescheduling on pain management of older lung cancer patients
氢可酮重新安排对老年肺癌患者疼痛管理的影响
基本信息
- 批准号:10599385
- 负责人:
- 金额:$ 47.1万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-09-23 至 2024-08-31
- 项目状态:已结题
- 来源:
- 关键词:AcuteAddressAffectAnalgesicsAnticonvulsantsAntidepressive AgentsCancer Pain ManagementCancer PatientCommunitiesComplexDataDistressFaceFutureGoalsHydrocodoneLeadLinkLiteratureMalignant NeoplasmsMalignant neoplasm of lungMedicalMedicareMedicare claimMedicare/MedicaidMetastatic Neoplasm to the BoneMorphineMuscle relaxantsNon-Steroidal Anti-Inflammatory AgentsOpioidOutcomePainPain managementPatientsPharmaceutical PreparationsPharmacotherapyPoliciesPopulationPostoperative PainPrevalenceProviderPublic HealthQuality of lifeResearchScheduleServicesSymptomsUnderserved PopulationUnited StatesUnited States Centers for Medicare and Medicaid Servicescancer carecancer health disparitycancer therapycancer typeclinical practicedata registrydisabling symptomdisparity reductiondual eligibleethnic minority populationexperiencehealth related quality of lifeimprovedinsightmilligrammultidisciplinaryneoplasm registrynon-opioid analgesicopioid epidemicopioid misuseopioid usepainful neuropathyprescription opioidprescription opioid misusepreventracial and ethnicresponsesurgical pain
项目摘要
Project Summary
Pain is a highly prevalent, complex, debilitating symptom for cancer patients. Pain
management is an essential component of cancer care. Adequate pain management can
significantly improve health-related quality of life for patients. However, there are substantial
disparities in access to adequate pain management especially among underserved and
underprivileged populations. Meanwhile, the opioid epidemic is a serious public health crisis,
and there have been many policy efforts to curb opioid misuse. One important policy change is
the rescheduling of hydrocodone from Schedule III to Schedule II in 2014 by the United States
Drug Enforcement Administration. However, prior literature has shown mixed evidence on the
actual overall impacts of this policy, as patients could either receive non-opioid
pharmacotherapy (e.g. nonsteroidal anti-inflammatory drugs, antidepressants, muscle relaxant,
anticonvulsants) or stronger opioids as replacements for hydrocodone. Additionally, few
studies examined the impact on pain management strategies and outcomes among cancer
patients, who may face potentially higher barriers to adequate pain management. Further, how
the policy change affects underserved and underprivileged groups is largely unknown.
We propose to use national cancer registry data linked with Medicare claims (SEER-
Medicare) to comprehensively examine the effects of the rescheduling of hydrocodone on older
lung cancer patients with a special focus on underserved and underprivileged groups. The
proposed study is well in line with the R21 RFA calling for research that utilizes Centers for
Medicare and Medicaid Services (CMS) administrative data to study pain management
strategies and outcomes, including underserved and underprivileged groups.
We will address the following aims: Aim 1. Examine the change in opioid and non-
opioid pharmacotherapy use among older lung cancer patients before and after the
rescheduling of hydrocodone from Schedule III to Schedule II. Aim 2. Compare the adequacy of
pain management in terms of prevalence of service use consistent with inadequate pain
management among older lung cancer patients before and after the rescheduling. Aim 3.
Examine potential disparities in the use of medications for pain management and service use
consistent with inadequate pain management among older lung cancer patients dually eligible
for both Medicare and Medicaid and among patients in racial/ethnic minority groups.
The proposed study will provide important insights to guide policy efforts and clinical
practice aimed at improving pain management and reducing disparities in cancer patients.
项目总结
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Chan Shen其他文献
Chan Shen的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Chan Shen', 18)}}的其他基金
Impact of the Diffusion of Robotic Surgical Systems on the Financial Performance, Market Shares, and Inpatient Costs of U.S. Hospitals
机器人手术系统的普及对美国医院财务业绩、市场份额和住院费用的影响
- 批准号:
9232093 - 财政年份:2016
- 资助金额:
$ 47.1万 - 项目类别:
相似海外基金
Rational design of rapidly translatable, highly antigenic and novel recombinant immunogens to address deficiencies of current snakebite treatments
合理设计可快速翻译、高抗原性和新型重组免疫原,以解决当前蛇咬伤治疗的缺陷
- 批准号:
MR/S03398X/2 - 财政年份:2024
- 资助金额:
$ 47.1万 - 项目类别:
Fellowship
Re-thinking drug nanocrystals as highly loaded vectors to address key unmet therapeutic challenges
重新思考药物纳米晶体作为高负载载体以解决关键的未满足的治疗挑战
- 批准号:
EP/Y001486/1 - 财政年份:2024
- 资助金额:
$ 47.1万 - 项目类别:
Research Grant
CAREER: FEAST (Food Ecosystems And circularity for Sustainable Transformation) framework to address Hidden Hunger
职业:FEAST(食品生态系统和可持续转型循环)框架解决隐性饥饿
- 批准号:
2338423 - 财政年份:2024
- 资助金额:
$ 47.1万 - 项目类别:
Continuing Grant
Metrology to address ion suppression in multimodal mass spectrometry imaging with application in oncology
计量学解决多模态质谱成像中的离子抑制问题及其在肿瘤学中的应用
- 批准号:
MR/X03657X/1 - 财政年份:2024
- 资助金额:
$ 47.1万 - 项目类别:
Fellowship
CRII: SHF: A Novel Address Translation Architecture for Virtualized Clouds
CRII:SHF:一种用于虚拟化云的新型地址转换架构
- 批准号:
2348066 - 财政年份:2024
- 资助金额:
$ 47.1万 - 项目类别:
Standard Grant
BIORETS: Convergence Research Experiences for Teachers in Synthetic and Systems Biology to Address Challenges in Food, Health, Energy, and Environment
BIORETS:合成和系统生物学教师的融合研究经验,以应对食品、健康、能源和环境方面的挑战
- 批准号:
2341402 - 财政年份:2024
- 资助金额:
$ 47.1万 - 项目类别:
Standard Grant
The Abundance Project: Enhancing Cultural & Green Inclusion in Social Prescribing in Southwest London to Address Ethnic Inequalities in Mental Health
丰富项目:增强文化
- 批准号:
AH/Z505481/1 - 财政年份:2024
- 资助金额:
$ 47.1万 - 项目类别:
Research Grant
ERAMET - Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
ERAMET - 快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10107647 - 财政年份:2024
- 资助金额:
$ 47.1万 - 项目类别:
EU-Funded
Ecosystem for rapid adoption of modelling and simulation METhods to address regulatory needs in the development of orphan and paediatric medicines
快速采用建模和模拟方法的生态系统,以满足孤儿药和儿科药物开发中的监管需求
- 批准号:
10106221 - 财政年份:2024
- 资助金额:
$ 47.1万 - 项目类别:
EU-Funded
Recite: Building Research by Communities to Address Inequities through Expression
背诵:社区开展研究,通过表达解决不平等问题
- 批准号:
AH/Z505341/1 - 财政年份:2024
- 资助金额:
$ 47.1万 - 项目类别:
Research Grant